Straits Times Index
3,307.28 -14.80 (-0.45%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,187.18 -179.77 (-0.98%) FTSE 100
8,243.24 +14.76 (+0.18%) Bitcoin USD
67,545.71 -1,787.75 (-2.58%) CMC Crypto 200
1,402.90 -38.74 (-2.69%)
BIIB Jul 2024 245.000 call
| Previous close | 2.4100 |
| Open | 2.4100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 245.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.4100 - 2.4100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceFDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
ZacksBiogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.
GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
